NeOnc secures $2.5M NIH grants for NEO212; finalizes $50M Quazar partnership

NEONC TECHNOLOGIES HOLDINGS, INC.

Awarded two NIH STTR grants totaling $2.5M to advance NEO212 in gliomas and leukemia.
$400K Phase 1 grant supports NEO212 preclinical study in AML; $2.1M Phase 2 grant targets newly diagnosed gliomas.
NuroMENA Holdings Ltd. incorporated by Abu Dhabi Global Market, clearing all contingencies for $50M investment from Quazar Investment.
Partnership will fund CNS platform launch in MENA region and accelerate NEO212/NEO100 clinical programs.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.